Peña OJ, Chávez BJMI

Language: Spanish
References: 22
Page: 40-45
PDF size: 392.04 Kb.

ABSTRACT

Autoimmune bullous diseases such as pemphigus vulgaris, pemphigoid, epidermolysis bullosa acquisita and linear IgA disease are the result from an abnormal immune response against to components of the basement membrane zone at the dermal-epidermal junction or desmosomes. Epidermolysis bullosa acquisita is a chronic blistering disease of skin and mucous membranes characterized by subepidermal blisters, is a rare disease with a prevalence of approximately 0.2/million people. There is no sex and racial predilection known to make a certain diagnose it is necessary to use molecular biology techniques, such as Immunohistochemistry. In this article we review current molecular aspects in the pathogenesis of this disease.

REFERENCES

1. Robinson ND, Hashimoto T, Amagai M et al. Continuing medical education: the new pemphigus variants. J Am Acad Dermatol 1999; 40: 649-671.

2. Patricio P, Ferreira C, Gomes C. Autoimmune bullous dermatoses: A review, annals of the New York Academy of Sciences. September 2009; 1173(1): 203-210.

3. Sitaru C, Goebeler M, Zillikens D. Bullous autoimmunedermatoses: pathogenesis and diagnosis. J Dtsch Dermatol Ges 2004; 2: 123-128.

4. Zhu X, Niimi Y, Bystryn J. Epidermolysis bullosa acquisita. Incidence in patients with basement membrane zone antibodies. Arch Dermatol 1990; 126: 171-174.

5. Tadashi N, Takekuni Y, Zillikens. Epidermolysis bullosa acquisita: What’s new? Journal of Dermatology 2010; 37(3): 220-230.

6. Woodley DT, Remington J, Chen M. Autoimmunity to type VII collagen: epidermolysis bullosa acquisita. Clin Rev Allergy Immunol 2007; 33: 78-84.

7. Nagy N, McGrath JA. Blistering skin diseases: a bridge between dermatopathology and molecular biology. Histopathology 2010; 56(1): 91-99.

8. Mihai S, Sitaru C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J Cell Mol Med 2007; 11: 462-481.

9. Mayuzumi M et al. Childhood epidermolysis bullosa acquisita with autoantibodies against the noncollagenous 1 and 2 domains of type VII collagen: case report and review of the literature. British Journal of Dermatology 2006; 155:1048-1052.

10. Mutasin D. Autoimmune bullous dermatoses in the elderly. Drugs Aging 2010; 27(1): 1-19.

11. Sitaru C. Experimental models of epidermolysis bullosa acquisita. Experimental Dermatology 2007; 16: 520-531.

12. Chen M, Chan LS, Cai X et al. Development of an ELISA for rapid detection of anti-type VII collagen autoantibodies in epidermolysis bullosa acquisita. J Invest Dermatol 1997; 108: 68-72.

13. Hallel-Halevy D, Nadelman C, Chen Met et al. Epidermolysis bullosa acquisita: update and review. Clin Dermatol 2001; 19: 712-718.

14. Engineer L, Ahmed AR. Emerging treatment for epidermolysis bullosa acquisita. J Am Acad Dermatol 2001; 44: 818-828.

15. Mutasim DF. Management of autoimmune bullous diseases: Pharmacology and therapeutics. J Am Acad Dermatol 2004; 51: 859-877.

16. Kirtschig G, Murrell D, Wojnarowska F et al. Interventions for mucous membrane pemphigoid ⁄ cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol 2002; 138: 380-384.

17. Schmidt E, Hopfner B, Chen C et al. Childhood epidermolysis bullosa acquisita: a novel variant with reactivity to all three structural domains of type VII collagen. Br J Dermatol 2002; 147: 592-597.

18. Woodley D, Chang C, Saadat P, Ram R, Liu Z, Chen M. Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J Invest Dermatol 2005; 124: 958-964.

19. Woodley D, Ram R, Doostan A et al. Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J Invest Dermatol 2006: 126: 1323-1330.

20. Ludwig R, Bieber K, Muller S. Generation of blister-inducing autoantibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita: P095 Experimental Dermatology 2010; 19(2): 182.

21. Ludwig R, Bieber K, Muller S. The role of cytokines and the major histocompatibility complex locus H2s insusceptibility to experimental epidermolysis bullosa acquisit. Experimental Dermatology 2010; 19(2): 179.

22. Kasperkiewicz M, Hirose M, Recke A. Clearance rates of circulating and tissue-bound autoantibodies to type VII collagen in experimental epidermolysis bullosa acquisita. British Journal of Dermatology 2010; 162(5): 1064-1070.